Opinion|Videos|October 11, 2024
Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches
Key Takeaways
- Drug interactions, patient characteristics, and steroid use are critical in LN management, influencing treatment choices and outcomes.
- Nephrologists focus on renal preservation, while rheumatologists emphasize controlling systemic lupus erythematosus, leading to differing treatment approaches.
Panelists discuss the considerations guiding treatment choices for lupus nephritis, such as drug interactions, patient characteristics, and steroid use, and how treatment approaches might differ between nephrologists and rheumatologists.
Advertisement
Episodes in this series
What considerations (eg, drug interactions, individual patient characteristics, steroid use) guide your treatment choices for managing lupus nephritis (LN)?
- How might treatment approaches for LN differ between nephrologists and rheumatologists?
Advertisement
Related to this article
Polyphenols show lab promise for endometriosis, but human evidence is thin, and the best resveratrol pain trial was negative.
Those using e-cigarettes were more likely to develop cataracts, and those receiving cataract surgery less likely to develop depression and anxiety.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.
An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
3
Using Complement Inhibitors in GA Comes With Pros and Cons
4
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
5